Kangmei Pharmaceutical (600518 CH) - First Class Action Lawsuit in China and Its Implications

256 Views16 Nov 2021 00:06
Guangzhou courts made a landmark ruling on a Class Action Lawsuit against Kangmei Pharmaceutical  This increases the costs of fraud and would boost investor's confidence in China's capital markets
SUMMARY
(Sign Up to Access)
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
  • Unlock all research summaries
  • Follow top, independent analysts
  • Receive personalised alerts and emails
  • Access Briefings, Analytics, and Events

Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.

Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 7-minute read)
Discussions
(Paid Plans Only)
chart-bar
x